Targeted Therapy for Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Adenomatous Polyposis, and Li-Fraumeni Syndrome

被引：0

作者：

Agarwal, Rishi ^{[1
]}

Liebe, Sarah ^{[2
]}

Turski, Michelle L. ^{[3
]}

Vidwans, Smruti J. ^{[3
]}

Janku, Filip ^{[4
]}

Garrido-Laguna, Ignacio ^{[5
]}

Munoz, Javier ^{[6
]}

Schwab, Richard ^{[7
]}

Rodon, Jordi ^{[8
,9
]}

Kurzrock, Razelle ^{[7
]}

Subbiah, Vivek ^{[4
]}

机构：

[1] Univ Cincinnati, Dept Med, Div Hematol Oncol, Cincinnati, OH 45267 USA

[2] Univ Texas Houston, UT Hlth, Houston, TX 77030 USA

[3] CollabRx Inc, San Francisco, CA 94104 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[6] Banner MD Anderson Canc Ctr, Gilbert, AZ 85234 USA

[7] Univ Calif San Diego, Ctr Personalized Canc Therapy, Moores Canc Ctr, San Diego, CA 92093 USA

[8] Vall dHebron Inst Oncol, Barcelona 08035, Spain

[9] Univ Autonoma Barcelona, Barcelona 08035, Spain

来源：

DISCOVERY MEDICINE | 2014年 / 18卷 / 101期

基金：

美国国家卫生研究院;

关键词：

BRCA1 MUTATION CARRIERS; COLORECTAL-CANCER; P53; MUTATIONS; GERMLINE MUTATIONS; RESISTANT STARCH; RECTAL ADENOMAS; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; CYCLOOXYGENASE-2; INHIBITOR; COLECTOMIZED PATIENTS;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Cancer genetics has rapidly evolved in the last two decades. Understanding and exploring the several genetic pathways in the cancer cell is the foundation of targeted therapy. Several genomic aberrations have been identified and their role in carcinogenesis is being explored. In contrast to most cancers where these mutations are acquired, patients with hereditary cancer syndromes have inherited genomic aberrations. The understanding of the molecular pathobiology in hereditary cancer syndromes has advanced dramatically. In addition, many molecularly targeted therapies have been developed that could have potential roles in the treatment of patients with hereditary cancer syndromes. In this review, we outline the presentation, molecular biology, and possible targeted therapies for two of the most widely recognized hereditary cancer syndromes - hereditary breast and ovarian cancer syndrome and hereditary non-polyposis colorectal cancer syndrome (Lynch syndrome). We will also discuss other syndromes such as familial adenomatous polyposis and Li-Fraumeni syndrome (TP53).

引用

页码：331 / 339

页数：9

共 89 条

[71] Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor in a phase II trial [J].